{"id":24972,"date":"2022-10-21T21:24:00","date_gmt":"2022-10-21T13:24:00","guid":{"rendered":"https:\/\/flcube.com\/?p=24972"},"modified":"2025-02-02T21:29:50","modified_gmt":"2025-02-02T13:29:50","slug":"hengruis-camrelizumab-and-akesos-ak112-set-to-receive-breakthrough-designation-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=24972","title":{"rendered":"Hengrui’s Camrelizumab and Akeso’s AK112 Set to Receive Breakthrough Designation in China"},"content":{"rendered":"\n

The Center for Drug Evaluation (CDE) website indicates that China-based Jiangsu Hengrui Medicine Co., Ltd\u2019s (SHA: 600276<\/a>) new indication filing for its programmed death-1 (PD-1) monoclonal antibody (mAb) camrelizumab, combined with the multi-kinase inhibitor famitinib, is set to receive Breakthrough Therapy Designation (BTD) status. The combination is intended as a first-line treatment for recurrent or metastatic non-small cell lung cancer (NSCLC) with positive PD-L1 expression in tumor cells (TPS \u2265 1%) and no EGFR\/ALK gene abnormality. Additionally, Akeso Biopharma\u2019s (9926.HK) AK112, a bispecific antibody (BsAb) targeting PD-1 and vascular endothelial growth factor (VEGF), is also set to receive BTD status for locally advanced or metastatic non-squamous NSCLC with EGFR mutations resistant to previous EGFR tyrosine kinase inhibitor (TKI) treatment.<\/p>\n\n\n\n

Camrelizumab: Market Approval and Development<\/strong>
Camrelizumab gained its first market approval in China in May 2019 for use as a third-line treatment for classic Hodgkin’s lymphoma. The drug is currently being developed for multiple indications, including hepatocellular carcinoma (HCC), NSCLC, esophageal squamous cell carcinoma, nasopharyngeal carcinoma, urinary tract tumors, and gynecological tumors, either as monotherapy or in combination with other drugs. Camrelizumab combined with famitinib are undergoing multiple clinical studies. The combination received BTD status for the treatment of recurrent metastatic cervical cancer in China in November 2020 and was approved for a Phase I\/II clinical study in advanced solid tumors when combined with paclitaxel (albumin-bound) a year later. Another clinical approval was secured in December 2021 to treat advanced solid tumors in combination with SHR-1802, an in-house developed lymphocyte activation gene 3 protein (LAG-3).<\/p>\n\n\n\n

Akeso’s AK112: Bispecific Antibody<\/strong>
Akeso’s self-developed AK112 is the world\u2019s first PD-1\/VEGF bispecific antibody to enter Phase III trials. The drug blocks the PD-1 and VEGF pathways simultaneously, aiming to produce synergistic anti-tumor effects. This innovative approach underscores Akeso’s commitment to advancing novel therapies for patients with challenging cancers.<\/p>\n\n\n\n

Future Outlook<\/strong>
The upcoming BTD status for both Hengrui’s camrelizumab combination and Akeso’s AK112 highlights the significant progress being made by Chinese biopharmaceutical companies in developing innovative cancer treatments. These designations are expected to accelerate the clinical development and market availability of these promising therapies, offering new hope for patients with non-small cell lung cancer and other advanced malignancies.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The Center for Drug Evaluation (CDE) website indicates that China-based Jiangsu Hengrui Medicine Co., Ltd\u2019s…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[34,29,2586,28,18,852,33],"class_list":["post-24972","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-breakthrough-therapy","tag-combination-therapy","tag-hengrui-pharmaceuticals","tag-multi-specific-antibodies","tag-pd-1-l1","tag-sha-600276","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"\nHengrui's Camrelizumab and Akeso's AK112 Set to Receive Breakthrough Designation in China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Center for Drug Evaluation (CDE) website indicates that China-based Jiangsu Hengrui Medicine Co., Ltd\u2019s (SHA: 600276) new indication filing for its programmed death-1 (PD-1) monoclonal antibody (mAb) camrelizumab, combined with the multi-kinase inhibitor famitinib, is set to receive Breakthrough Therapy Designation (BTD) status. The combination is intended as a first-line treatment for recurrent or metastatic non-small cell lung cancer (NSCLC) with positive PD-L1 expression in tumor cells (TPS \u2265 1%) and no EGFR\/ALK gene abnormality. Additionally, Akeso Biopharma\u2019s (9926.HK) AK112, a bispecific antibody (BsAb) targeting PD-1 and vascular endothelial growth factor (VEGF), is also set to receive BTD status for locally advanced or metastatic non-squamous NSCLC with EGFR mutations resistant to previous EGFR tyrosine kinase inhibitor (TKI) treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=24972\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui's Camrelizumab and Akeso's AK112 Set to Receive Breakthrough Designation in China\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=24972\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-21T13:24:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-02T13:29:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24972#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24972\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui’s Camrelizumab and Akeso’s AK112 Set to Receive Breakthrough Designation in China\",\"datePublished\":\"2022-10-21T13:24:00+00:00\",\"dateModified\":\"2025-02-02T13:29:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24972\"},\"wordCount\":385,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Breakthrough therapy\",\"Combination therapy\",\"Hengrui Pharmaceuticals\",\"Multi-specific antibodies\",\"PD-1\\\/L1\",\"SHA: 600276\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24972#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24972\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=24972\",\"name\":\"Hengrui's Camrelizumab and Akeso's AK112 Set to Receive Breakthrough Designation in China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-10-21T13:24:00+00:00\",\"dateModified\":\"2025-02-02T13:29:50+00:00\",\"description\":\"The Center for Drug Evaluation (CDE) website indicates that China-based Jiangsu Hengrui Medicine Co., Ltd\u2019s (SHA: 600276) new indication filing for its programmed death-1 (PD-1) monoclonal antibody (mAb) camrelizumab, combined with the multi-kinase inhibitor famitinib, is set to receive Breakthrough Therapy Designation (BTD) status. The combination is intended as a first-line treatment for recurrent or metastatic non-small cell lung cancer (NSCLC) with positive PD-L1 expression in tumor cells (TPS \u2265 1%) and no EGFR\\\/ALK gene abnormality. Additionally, Akeso Biopharma\u2019s (9926.HK) AK112, a bispecific antibody (BsAb) targeting PD-1 and vascular endothelial growth factor (VEGF), is also set to receive BTD status for locally advanced or metastatic non-squamous NSCLC with EGFR mutations resistant to previous EGFR tyrosine kinase inhibitor (TKI) treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24972#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24972\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24972#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui’s Camrelizumab and Akeso’s AK112 Set to Receive Breakthrough Designation in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui's Camrelizumab and Akeso's AK112 Set to Receive Breakthrough Designation in China - Insight, China's Pharmaceutical Industry","description":"The Center for Drug Evaluation (CDE) website indicates that China-based Jiangsu Hengrui Medicine Co., Ltd\u2019s (SHA: 600276) new indication filing for its programmed death-1 (PD-1) monoclonal antibody (mAb) camrelizumab, combined with the multi-kinase inhibitor famitinib, is set to receive Breakthrough Therapy Designation (BTD) status. The combination is intended as a first-line treatment for recurrent or metastatic non-small cell lung cancer (NSCLC) with positive PD-L1 expression in tumor cells (TPS \u2265 1%) and no EGFR\/ALK gene abnormality. Additionally, Akeso Biopharma\u2019s (9926.HK) AK112, a bispecific antibody (BsAb) targeting PD-1 and vascular endothelial growth factor (VEGF), is also set to receive BTD status for locally advanced or metastatic non-squamous NSCLC with EGFR mutations resistant to previous EGFR tyrosine kinase inhibitor (TKI) treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=24972","og_locale":"en_US","og_type":"article","og_title":"Hengrui's Camrelizumab and Akeso's AK112 Set to Receive Breakthrough Designation in China","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=24972","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-10-21T13:24:00+00:00","article_modified_time":"2025-02-02T13:29:50+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=24972#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=24972"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui’s Camrelizumab and Akeso’s AK112 Set to Receive Breakthrough Designation in China","datePublished":"2022-10-21T13:24:00+00:00","dateModified":"2025-02-02T13:29:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=24972"},"wordCount":385,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Breakthrough therapy","Combination therapy","Hengrui Pharmaceuticals","Multi-specific antibodies","PD-1\/L1","SHA: 600276","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=24972#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=24972","url":"https:\/\/flcube.com\/?p=24972","name":"Hengrui's Camrelizumab and Akeso's AK112 Set to Receive Breakthrough Designation in China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-10-21T13:24:00+00:00","dateModified":"2025-02-02T13:29:50+00:00","description":"The Center for Drug Evaluation (CDE) website indicates that China-based Jiangsu Hengrui Medicine Co., Ltd\u2019s (SHA: 600276) new indication filing for its programmed death-1 (PD-1) monoclonal antibody (mAb) camrelizumab, combined with the multi-kinase inhibitor famitinib, is set to receive Breakthrough Therapy Designation (BTD) status. The combination is intended as a first-line treatment for recurrent or metastatic non-small cell lung cancer (NSCLC) with positive PD-L1 expression in tumor cells (TPS \u2265 1%) and no EGFR\/ALK gene abnormality. Additionally, Akeso Biopharma\u2019s (9926.HK) AK112, a bispecific antibody (BsAb) targeting PD-1 and vascular endothelial growth factor (VEGF), is also set to receive BTD status for locally advanced or metastatic non-squamous NSCLC with EGFR mutations resistant to previous EGFR tyrosine kinase inhibitor (TKI) treatment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=24972#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=24972"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=24972#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui’s Camrelizumab and Akeso’s AK112 Set to Receive Breakthrough Designation in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24972"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24972\/revisions"}],"predecessor-version":[{"id":24973,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24972\/revisions\/24973"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24972"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24972"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}